Simplify Logo

Full-Time

Senior Director

Clinical Science

Confirmed live in the last 24 hours

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops advanced cell therapies for cancer

Healthcare
Biotechnology

Compensation Overview

$255k - $280kAnnually

+ Annual Bonus + Equity Incentive Plan

Senior, Expert

Seattle, WA, USA + 1 more

More locations: Washington, USA

Role can be based in Seattle, WA or South San Francisco, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • PhD or PharmD with a minimum of 15 years’ scientific and/or clinical experience in immunology, oncology, molecular biology, health care delivery, or
  • MSc with a minimum of 17 years’ scientific and/or clinical experience in immunology, oncology, molecular biology, health care delivery, or
  • BSRN with a minimum of 20 years’ scientific and/or clinical experience in immunology, oncology, molecular biology, health care delivery
  • A minimum of 5 years’ experience in clinical development, with substantial experience in the pharmaceutical industry contributing to successful clinical programs.
  • Phase 1 clinical trials experience.
  • Demonstrated experience in the design, execution, and oversight of clinical trials.
  • Strong analytical, organizational, and communication skills.
  • Ability to lead program/project teams effectively in a collaborative, fast-paced environment.
  • Ability to manage multiple priorities in a fast-paced, dynamic environment.
Responsibilities
  • Under guidance from the physician, drive the design and development of clinical trial protocols, ensuring they meet scientific, medical and regulatory requirements.
  • Prepare and review documents for regulatory submissions (IND, BLA, etc.), including clinical study reports, Investigator’s Brochures, and responses to regulatory agency inquiries.
  • Support the execution of clinical trials, ensuring adherence to the protocol, regulatory requirements, and Good Clinical Practice (GCP) guidelines.
  • Coordinate with data management teams to ensure accurate data collection, analysis, and reporting. Review and interpret clinical data to make informed decisions about study progression.
  • Monitor patient safety, identifying and managing adverse events, and ensuring timely reporting to regulatory bodies.
  • Provide leadership and support to clinical operations, biostatistics, regulatory affairs, and other departments to ensure seamless trial execution; identify issues and recommend solutions for immediate action.
  • Liaise with external stakeholders, including clinical research organizations (CROs), academic institutions, and key opinion leaders (KOLs); provide leadership and direction in identifying and solving issues to facilitate trial operations and maintain high standards of scientific integrity.
  • Define opportunities for innovation and improvement in clinical trial methodologies and therapeutic approaches.
  • Anticipate risk and proactively manage concerns; define actions to address issues in a timely manner.

Lyell Immunopharma develops advanced cell therapies specifically designed to treat solid tumors, which are cancerous tissue masses. Their approach focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. The company addresses significant challenges in cancer treatment by employing technologies like Gen-R and Epi-R, which involve modifying the genes and gene expression in T cells to prevent T cell exhaustion and promote their ability to persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments for solid tumors, leveraging a diverse product pipeline and a team of experts in oncology and adoptive cell therapy. The ultimate goal is to push the limits of current cancer therapies and provide effective solutions for patients where traditional methods have not succeeded.

Company Stage

IPO

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2018

Growth & Insights
Headcount

6 month growth

-4%

1 year growth

-20%

2 year growth

-13%
Simplify Jobs

Simplify's Take

What believers are saying

  • Lyell's strategic partnerships, such as with MaxCyte and AWS, enhance their technological capabilities and operational efficiency.
  • The appointment of experienced leaders like Lynn Seely as CEO and Matthew Lang as Chief Business Officer strengthens the company's executive team.
  • Their state-of-the-art manufacturing facility in Bothell, Washington, supports the scalability and testing of their proprietary technologies.

What critics are saying

  • The company is still awaiting critical clinical data, which could impact investor confidence and future funding.
  • High turnover in key management positions, such as the departure of the General Counsel, may lead to strategic and operational disruptions.

What makes Lyell Immunopharma unique

  • Lyell Immunopharma focuses on T cell reprogramming to treat solid tumors, a niche area with fewer competitors compared to broader oncology treatments.
  • Their proprietary technologies, Gen-R and Epi-R, offer unique solutions to T cell exhaustion and lack of durable stemness, setting them apart from other cell therapy companies.
  • The company's commitment to scientific innovation is underscored by a world-class team of experts in oncology and adoptive cell therapy.